New antimicrobials in ophthalmology

Ophthalmology Clinics of North America

Volumn 18, Issue 4, 2005, Pages 493-509

  Levinson, Brett A ^a   Rutzen, Allan R ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BACITRACIN; BENZALKONIUM CHLORIDE; BILIRUBIN GLUCURONIDE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CREATININE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; LIVER ENZYME; MOXIFLOXACIN; NALIDIXIC ACID; NEOMYCIN; OFLOXACIN; OXACILLIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAFURAZOLE; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; CHEILITIS; CHEMOSIS; CLINICAL TRIAL; COLOR VISION DEFECT; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA ULCER; CORNEAL PRECIPITATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRY EYE; ENDOPHTHALMITIS; EYE INFECTION; EYE IRRITATION; EYE PAIN; EYELID EDEMA; FACE ERYTHEMA; FOREIGN BODY SENSATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPEREMIA; INSOMNIA; KERATITIS; LACRIMATION; MINIMUM INHIBITORY CONCENTRATION; MIOSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OCULAR PRURITUS; OPHTHALMOLOGY; PAPILLARY CONJUNCTIVITIS; PHLEBITIS; PHOTOPHOBIA; PHOTOPSIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; SEPSIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; TASTE DISORDER; TENDON RUPTURE; THROMBOCYTOPENIA; URTICARIA; VENOUS IRRITATION; VIRUS INFECTION; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

ANTI-BACTERIAL AGENTS; EYE INFECTIONS; HUMANS; OPHTHALMOLOGY;

EID: 28444483967     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2005.08.002     Document Type: Review

References (84)

1. Anonymous Looking back on the millennium in medicine N Engl J Med 342 1 2000 42 49
2. P.M. Dunn Dr Carl Crede (1819-1892) and the prevention of ophthalmia neonatorum Arch Dis Child Fetal Neonatal Ed 83 2000 F158 F159
3. T.M. Daniel, and A. Selman Waksman and the first use of streptomycin J Lab Clin Med 111 1 1988 133 134
4. F.S. Mah New antibiotics for bacterial infections Ophthalmol Clin North Am 16 1 2003 11 27
5. P.U. Fechner, and K.D. Teichmann Ocular therapeutics: pharmacology and clinical application 1998 SLACK Thorofare, NJ
6. L.S. Goodman, J.G. Hardman, and L.E. Limbird Goodman and Gilman's the pharmacological basis of therapeutics 10th edition 2001 McGraw-Hill New York
7. M.K. Rhee, R.P. Kowalski, and E.G. Romanowski A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa Am J Ophthalmol 138 2 2004 226 230
8. Fechner PUTK Ocular therapeutics: pharmacology and clinical application 1998 SLACK Thorofare, NJ
9. I.S. Yalvac, N.E. Basci, and A. Bozkurt Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous J Cataract Refract Surg 29 3 2003 487 491
10. D. Rhee, C.J. Rappuano, and C.A. Weisbecker Physicians' desk reference for ophthalmic medicines, vol. 32 2004 Thomson PDR Montvale, NJ v
11. T.P. O'Brien, M.G. Maguire, and N.E. Fink Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group Arch Ophthalmol 113 10 1995 1257 1265
12. A. Panda, R. Ahuja, and S.S. Sastry Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis Eye 13 Pt 6 1999 744 747
13. S. Khokhar, N. Sindhu, and B.R. Mirdha Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis Infection 28 3 2000 149 152
14. R.A. Hyndiuk, R.A. Eiferman, and D.R. Caldwell Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group Ophthalmology 103 11 1996 1854 1862
15. R. Beck, J. van Keyserlingk, and U. Fischer Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes Graefes Arch Clin Exp Ophthalmol 237 2 1999 89 92
16. L.S. Snyder-Perlmutter, H.R. Katz, and M. Melia Effect of topical ciprofloxacin 0.3% and ofloxacin 0.3% on the reduction of bacterial flora on the human conjunctiva J Cataract Refract Surg 26 11 2000 1620 1625
17. A. Graves, M. Henry, and T.P. O'Brien In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones Cornea 20 3 2001 301 305
18. D. Miller, and E.C. Alfonso Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates Cornea 23 3 2004 289 293
19. F.W. Price Jr, W.E. Whitson, and K.S. Collins Corneal tissue levels of topically applied ciprofloxacin Cornea 14 2 1995 152 156
20. A.G. Akkan, I. Mutlu, and S. Ozyazgan Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye J Chemother 9 4 1997 257 262
21. M.L. McDermott, T.D. Tran, and J.W. Cowden Corneal stromal penetration of topical ciprofloxacin in humans Ophthalmology 100 2 1993 197 200
22. S.M. Ghazi-Nouri, J. Lochhead, and A.A. Mearza Penetration of oral and topical ciprofloxacin into the aqueous humour Clin Experiment Ophthalmol 31 1 2003 40 43
23. F.A. Bucci Jr An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification Am J Ophthalmol 137 2 2004 308 312
24. S.M. Ghazi-Nouri Penetration of topical ciprofloxacin into the aqueous J Cataract Refract Surg 29 11 2003 2043 2044
25. J. Colin, S. Simonpoli, and K. Geldsetzer Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin Acta Ophthalmol Scand 81 6 2003 611 613
26. M.K. Jensen, R.G. Fiscella, and A.S. Crandall A retrospective study of endophthalmitis rates comparing quinolone antibiotics Am J Ophthalmol 139 1 2005 141 148
27. F.B. Marangon, D. Miller, and M.S. Muallem Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis Am J Ophthalmol 137 3 2004 453 458
28. R.P. Kowalski, A.N. Pandya, and L.M. Karenchak An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa Ophthalmology 108 10 2001 1826 1829
29. R. Mather, L.M. Karenchak, and E.G. Romanowski Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics Am J Ophthalmol 133 4 2002 463 466
30. R.P. Kowalski, D.K. Dhaliwal, and L.M. Karenchak Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates Am J Ophthalmol 136 3 2003 500 505
31. Susceptibility of bacterial isolates: the Charles T. Campbell Eye Microbiology Lab Available at: http://eyemicrobiology.upmc.com Accessed July 1, 2005
32. R. Solomon, E.D. Donnenfeld, and H.D. Perry Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor Ophthalmology 112 3 2005 466 469
33. J.M. Levine, R.J. Noecker, and L.C. Lane Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing J Cataract Refract Surg 30 10 2004 2177 2182
34. R.P. Kowalski, E.G. Romanowski, and F.S. Mah Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model Am J Ophthalmol 138 1 2004 33 37
35. T.A. Kovoor, A.S. Kim, and J.P. McCulley Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy Eye Contact Lens 30 2 2004 90 94
36. L.A. Herrygers, R.J. Noecker, and L.C. Lane Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols Cornea 24 1 2005 66 71
37. E. Donnenfeld, H.D. Perry, and D.A. Chruscicki A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability Curr Med Res Opin 20 11 2004 1753 1758
38. R.P. Kowalski, L.M. Karenchak, and A.W. Eller The role of ciprofloxacin in endophthalmitis therapy Am J Ophthalmol 116 6 1993 695 699
39. S.M. Hariprasad, W.F. Mieler, and E.R. Holz Vitreous and aqueous penetration of orally administered gatifloxacin in humans Arch Ophthalmol 121 3 2003 345 350
40. M.C. Garcia-Saenz, A. Arias-Puente, and M.J. Fresnadillo-Martinez Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin J Cataract Refract Surg 27 12 2001 1969 1974
41. M.S. Benz, I.U. Scott, and H.W. Flynn Jr Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases Am J Ophthalmol 137 1 2004 38 42
42. Endophthalmitis Vitrectomy Study Group Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis Arch Ophthalmol 113 12 1995 1479 1496
43. H.E. Aguilar, T.A. Meredith, and A. Shaarawy Vitreous cavity penetration of ceftazidime after intravenous administration Retina 15 2 1995 154 159
44. A. el-Massry, T.A. Meredith, and H.E. Aguilar Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration Am J Ophthalmol 122 5 1996 684 689
45. R.G. Fiscella, W.W. Lai, and B. Buerk Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration Ophthalmology 111 6 2004 1191 1195
46. E.G. Vazquez, J. Mensa, and Y. Lopez Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration Antimicrob Agents Chemother 48 2 2004 670 672
47. Ekdawi N.S., Fiscella R., Schreckenberger P., et al. Topical linezolid in Streptococcus Pneumoniae corneal ulcer model in rabbits. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, May 1-5, 2005
48. Elhosn R.R., Squires A., Emmert-Buck L., et al. Topical linezolid for the treatment of vancomycin resistant Enterococcus crystalline keratopathy after penetrating keratoplasty. Presented at the Annual Conference of the Association for Cataract and Refractive Surgeons. San Diego, May 1-5, 2004
49. T.S. Lundstrom, and J.D. Sobel Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin Infect Dis Clin North Am 18 3 2004 651 668
50. R.A. Padmanabhan, S.P. Larosa, and K.J. Tomecki What's new in antibiotics? Dermatol Clin 23 2 2005 301 312
51. Harper T., Miller D., Flynn Jr H.W. In vitro efficacy of alternatives to moxifloxacin and gatifloxacin for coagulase-negative Staphylococcus. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, May 1-5, 2005
52. I.U. Scott, R.H. Loo, and H.W. Flynn Jr Endophthalmitis caused by enterococcus faecalis: antibiotic selection and treatment outcomes Ophthalmology 110 8 2003 1573 1577
53. Herpetic Eye Disease Study Group Acyclovir for the prevention of recurrent herpes simplex virus eye disease N Engl J Med 339 5 1998 300 306
54. S. Weller, M.R. Blum, and M. Doucette Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers Clin Pharmacol Ther 54 6 1993 595 605
55. J. Soul-Lawton, E. Seaber, and N. On Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans Antimicrob Agents Chemother 39 12 1995 2759 2764
56. J. Colin, O. Prisant, and B. Cochener Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus Ophthalmology 107 8 2000 1507 1511
57. K.H. Fife, R.A. Barbarash, and T. Rudolph Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group Sex Transm Dis 24 8 1997 481 486
58. L. Corey, A. Wald, and R. Patel Once-daily valacyclovir to reduce the risk of transmission of genital herpes N Engl J Med 350 1 2004 11 20
59. W.R. Lin, H.H. Lin, and S.S. Lee Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster J Microbiol Immunol Infect 34 2 2001 138 142
60. D. Ormrod, L.J. Scott, and C.M. Perry Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections Drugs 59 4 2000 839 863
61. S.K. Tyring, K.R. Beutner, and B.A. Tucker Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older Arch Fam Med 9 9 2000 863 869
62. F. Diaz-Mitoma, R.G. Sibbald, and S.D. Shafran Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group JAMA 280 10 1998 887 892
63. J. Cohen, W.G. Powderly, and S. Berkley Infectious diseases 2nd edition 2004 Mosby Edinburgh, Scotland
64. D.F. Martin, J. Sierra-Madero, and S. Walmsley A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis N Engl J Med 346 15 2002 1119 1126
65. R.S. Cvetkovic, and K. Wellington Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients Drugs 65 6 2005 859 878
66. B.R. Kosobucki, D.E. Goldberg, and K. Bessho Valganciclovir therapy for immune recovery uveitis complicated by macular edema Am J Ophthalmol 137 4 2004 636 638
67. V. Savant, T. Saeed, and A. Denniston Oral valganciclovir treatment of varicella zoster virus acute retinal necrosis Eye 18 5 2004 544 545
68. R. Peck, S.K. Gimple, and D.W. Gregory Progressive outer retinal necrosis in a 73-year-old man: treatment with valganciclovir AIDS 17 7 2003 1110 1111
69. S.M. Hariprasad, W.F. Mieler, and E.R. Holz Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans Arch Ophthalmol 122 1 2004 42 47
70. A.K. Gupta, and E. Tomas New antifungal agents Dermatol Clin 21 3 2003 565 576
71. F.B. Marangon, D. Miller, and J.A. Giaconi In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens Am J Ophthalmol 137 5 2004 820 825
72. H. Gao, M.E. Pennesi, and K. Shah Intravitreal voriconazole: an electroretinographic and histopathologic study Arch Ophthalmol 122 11 2004 1687 1692
73. S.M. Breit, S.M. Hariprasad, and W.F. Mieler Management of endogenous fungal endophthalmitis with voriconazole and caspofungin Am J Ophthalmol 139 1 2005 135 140
74. J.M. Granados, N. Puerto, and M.J. Carrilero [Efficiency of voriconazole in fungal keratitis caused by candida albicans] Arch Soc Esp Oftalmol 79 11 2004 565 568 [in Spanish]
75. J.E. Kim, S.L. Perkins, and G.J. Harris Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection Arch Ophthalmol 121 5 2003 735 737
76. A. Reis, R. Sundmacher, and K. Tintelnot Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole Br J Ophthalmol 84 8 2000 932 933
77. W.E. Sponsel, J.R. Graybill, and H.L. Nevarez Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis Br J Ophthalmol 86 7 2002 829 830
78. D. Goldblum, B.E. Frueh, and G.M. Sarra Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model Antimicrob Agents Chemother 49 4 2005 1359 1363
79. O. Cekic, C. Batman, and Y. Totan Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration Ophthalmic Surg Lasers 30 6 1999 465 468
80. L.B. Cantor, E. Donnenfeld, and L.J. Katz Penetration of ofloxacin and ciprofloxacin into the aqueous humor of eyes with functioning filtering blebs: a randomized trial Arch Ophthalmol 119 9 2001 1254 1257
81. E.D. Donnenfeld, A. Schrier, and H.D. Perry Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor Ophthalmology 101 5 1994 902 905
82. Robertson S., Sanders M., Jasheway D., et al. Absorption and distribution of moxifloxacin, ofloxacin and gatifloxacin into ocular tissues and plasma following topical ocular administration to pigmented rabbits. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, April 25-29, 2004
83. th edition 2004 Thompson PDR Montvale (NJ) 58
84. R. Courtney, A. Sansone, and W. Smith Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease J Clin Pharmacol 45 2 2005 185 192